Current and future therapeutic options for persistent pulmonary hypertension in the newborn

References

• Gersony W, Duc G, Sinclair J. ‘PFC syndrome’ (persistence of the fetal circulation). Circulation40(Suppl. 3), 87(1969).
   PubMed Web of Science ®Google Scholar
• Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology91(4), 283–290 (2007).
   PubMed Web of Science ®Google Scholar
• Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT.Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. J. Pediatr.140(3), 306–310 (2002).
   PubMed Web of Science ®Google Scholar
• Ivy DD, Parker TA, Kinsella JP, Abman SH. Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Pediatr. Res.44(2), 175–180 (1998).
   PubMed Web of Science ®Google Scholar
• Muraskas JK, Juretschke LJ, Weiss MG, Bhola M, Besinger RE. Neonatal–perinatal risk factors for the development of persistent pulmonary hypertension of the newborn in preterm newborns. Am. J. Perinatol.18(2), 87–91 (2001).
   PubMed Web of Science ®Google Scholar
• Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr. Res.36(3), 402–408 (1994).
   PubMed Web of Science ®Google Scholar
• Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr. Clin. North Am.56(3), 579–600 (2009).
   PubMed Web of Science ®Google Scholar
• Jankov RP, McNamara PJ. Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn: when is it enough? J. Crit. Care20(3), 294–295 (2005).
   PubMed Web of Science ®Google Scholar
• Steinhorn RH, Kinsella JP, Pierce C et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J. Pediatr.155(6), 841–847.e1 (2009).
   PubMed Web of Science ®Google Scholar
• Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin. Perinatol.29(1), 8–14 (2005).
   PubMed Web of Science ®Google Scholar
• Steinhorn RH. Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J. Perinatol.28(Suppl. 3), S67–S71 (2008).
   PubMed Web of Science ®Google Scholar
• Palmer R, Ferrige A, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature327(6122), 524–526 (1987).
   PubMed Web of Science ®Google Scholar
• Steudel W, Hurford W, Zapol W. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology91(4), 1090–1121 (1999).
   PubMed Web of Science ®Google Scholar
• Bloch K, Ichinose F, Roberts J Jr, Zapol W. Inhaled NO as a therapeutic agent. Cardiovasc. Res.75(2), 339–348 (2007).
   PubMed Web of Science ®Google Scholar
• Fagan K, Tyler R, Sato K et al. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am. J. Physiol.277(3 Pt 1), L472–L478 (1999).
   PubMed Web of Science ®Google Scholar
• Bin-Nun A, Schreiber M. Role of iNO in the modulation of pulmonary vascular resistance. J. Perinatol.28(Suppl. 3), S84–S92 (2008).
   PubMed Web of Science ®Google Scholar
• Hare J, Stamler J. NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest.115(3), 509–517 (2005).
   PubMed Web of Science ®Google Scholar
• Shekerdemian L, Ravn H, Penny D. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr. Res.55(3), 413–418 (2004).
   PubMed Web of Science ®Google Scholar
• Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst. Rev.4, CD000399 (2006).
   PubMedGoogle Scholar
• Soll RF. Inhaled nitric oxide in the neonate. J. Perinatol.29(Suppl. 2), S63–S67 (2009).
   PubMed Web of Science ®Google Scholar
• Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst. Rev.3, CD001340 (2008).
   Google Scholar
• Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics90(6), 899–904 (1992).
   PubMed Web of Science ®Google Scholar
• Skimming JW, DeMarco VG, Cassin S. The effects of nitric oxide inhalation on the pulmonary circulation of preterm lambs. Pediatr. Res.37(1), 35–40 (1995).
   PubMed Web of Science ®Google Scholar
• Issa A, Lappalainen U, Kleinman M, Bry K, Hallman M. Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits. Pediatr. Res.45(2), 247–254 (1999).
   PubMed Web of Science ®Google Scholar
• Kinsella J, Parker T, Galan H, Sheridan B, Halbower A, Abman S. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr. Res.41(4 Pt 1), 457–463 (1997).
   PubMed Web of Science ®Google Scholar
• Cotton R, Sundell H, Zeldin D et al. Inhaled nitric oxide attenuates hyperoxic lung injury in lambs. Pediatr. Res.59(1), 142–146 (2006).
   PubMed Web of Science ®Google Scholar
• McCurnin D, Pierce R, Chang L et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am. J. Physiol. Lung Cell Mol. Physiol.288(3), L450–L459 (2005).
   PubMed Web of Science ®Google Scholar
• Tang J, Markham N, Lin Y et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am. J. Physiol. Lung Cell Mol. Physiol.287(2), L344–L351 (2004).
   PubMed Web of Science ®Google Scholar
• Lin Y, Markham N, Balasubramaniam V et al. Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr. Res.58(1), 22–29 (2005).
   PubMed Web of Science ®Google Scholar
• Barrington K, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst. Rev.3, CD000509 (2007).
   Google Scholar
• Su P, Chen J. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure. J. Perinatol.28(2), 112–116 (2008).
   PubMed Web of Science ®Google Scholar
• Mercier J. The effects of nitric oxide for inhalation on the development of chronic lung disease in pre-term neonates. Presented at: 2nd Congress of the European Academy of Paediatrics. Nice, France, 24–28 October 2008.
   Google Scholar
• Hibbs A, Walsh M, Martin R et al. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to Prevent) Chronic Lung Disease trial. J. Pediatr.153(4), 525–529 (2008).
   PubMed Web of Science ®Google Scholar
• Huddy C, Bennett C, Hardy P et al. The INNOVO multicentre randomised controlled trial: neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for severe respiratory failure in preterm infants: follow up at 4–5 years. Arch. Dis. Child Fetal Neonatal Ed.93(6), F430–F435 (2008).
   PubMedGoogle Scholar
• Kinsella J, Cutter G, Walsh W et al. Outcomes of premature neonates enrolled in the Early Inhaled Nitric Oxide for the Prevention of Chronic Lung Disease Trial. Abstract in Pediatric Academic Societies’ annual meeting. E-PAS2155.6 (2009).
   Google Scholar
• Mercier JC, Olivier P, Loron G, Fontaine R, Maury L, Baud O. Inhaled nitric oxide to prevent bronchopulmonary dysplasia in preterm neonates. Semin. Fetal Neonatal Med.14(1), 28–34 (2009).
   PubMed Web of Science ®Google Scholar
• Travadi J, Patole S. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr. Pulmonol.36(6), 529–535 (2003).
   PubMed Web of Science ®Google Scholar
• Ichinose F, Erana-Garcia J, Hromi J et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit. Care Med.29(5), 1000–1005 (2001).
   PubMed Web of Science ®Google Scholar
• Kleinsasser A, Loeckinger A, Hoermann C et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am. J. Respir. Crit. Care Med.163(2), 339–343 (2001).
   PubMed Web of Science ®Google Scholar
• Shekerdemian L, Ravn H, Penny D. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am. J. Respir. Crit. Care Med.165(8), 1098–1102 (2002).
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J.30(4), 394–403 (2009).
   PubMed Web of Science ®Google Scholar
• Stocker C, Penny D, Brizard C, Cochrane A, Soto R, Shekerdemian L. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med.29(11), 1996–2003 (2003).
   PubMed Web of Science ®Google Scholar
• Namachivayam P, Theilen U, Butt W, Cooper S, Penny D, Shekerdemian L. sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am. J. Respir. Crit. Care Med.174(9), 1042–1047 (2006).
   PubMed Web of Science ®Google Scholar
• Peiravian F, Amirghofran A, Borzouee M, Ajami G, Sabri M, Kolaee S. Oral sildenafil to control pulmonary hypertension after congenital heart surgery. Asian Cardiovasc. Thorac. Ann.15(2), 113–117 (2007).
   PubMedGoogle Scholar
• Shah P, Ohlsson A. sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst. Rev.3, CD005494 (2007).
   Google Scholar
• Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics117(4), 1077–1083 (2006).
   PubMed Web of Science ®Google Scholar
• Herrea J, Castillo R, Concha E, Soliz A. Oral sildenafil treatment as an alternative to inhaled NO therapy for persistent pulmonary hypertension of the newborn. Abstract in Pediatric Academic Societies’ annual meeting. E-PAS3724.3 (2006).
   Google Scholar
• Soliz A, Concha E, Romero F. Oral sildenafil treatment as therapy for persistent pulmonary hypertension of the newborn: a multicentre randomized trial. Abstract in Pediatric Academic Societies’ annual meeting. E-PAS5420.12 (2009).
   Google Scholar
• Vargas-Origel A, Gomez-Rodriguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcon-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am. J. Perinatol.27(3), 225–230 (2009).
   PubMed Web of Science ®Google Scholar
• Baquero H, Venegas M, Lorena V, Fredy N, Augusto S. Neurological follow-up (12–48 months) to patients treated with oral sildenafil for severe neonatal pulmonary hypertension in NICU where the iON is not available. Abstract in Pediatric Academic Societies’ annual meeting. E-PAS3772.2 (2008).
   Google Scholar
• Baquero H, Neira F, Venegas M, Sola A, Soliz A. Outcome at 18 months of age after sildenafil therapy for refractory neonatal hypoxemia. Abstract in Pediatric Academic Societies’ annual meeting. E-PAS2119 (2005).
   Google Scholar
• Noori S, Friedlich P, Wong P, Garingo A, Seri I. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology91(2), 92–100 (2007).
   PubMed Web of Science ®Google Scholar
• Benavides II, Domonoske C, Lally K, Khan A. The use of sildenafil in infants with refractory pulmonary hypertension secondary to congenital diaphragmatic hernia – one center’s experience. Abstract in: Pediatric Academic Societies’ Annual Meeting. E-PAS447 (2006).
   Google Scholar
• Lima V, Roque R, Villegas C, Escalante F, Torres A, Leija L. Sildenafil for persistent pulmonary hypertension of the newborn: report of two cases. PAS57, 1242 (2005).
   Google Scholar
• Cavallaro G, Agazzani E, Andaloro L et al. sildenafil and nitric oxide inhalation in neonatal pulmonary hypertension. Three case reports. Pediatr. Med. Chir.30(3), 149–155 (2008).
   PubMedGoogle Scholar
• Obaid L, Johnson S, Bigam D, Cheung P. Intratracheal administration of sildenafil and surfactant alleviates the pulmonary hypertension in newborn piglets. Resuscitation69(2), 287–294 (2006).
   PubMed Web of Science ®Google Scholar
• Martell M, Blasina F, Silvera F et al. Intratracheal sildenafil in the newborn with pulmonary hypertension. Pediatrics119(1), 215–216 (2007).
   PubMed Web of Science ®Google Scholar
• Shipley J, Tolman D, Hastillo A, Hess M. Milrinone: basic and clinical pharmacology and acute and chronic management. Am. J. Med. Sci.311(6), 286–291 (1996).
   PubMed Web of Science ®Google Scholar
• Deb B, Bradford K, Pearl R. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit. Care Med.28(3), 795–799 (2000).
   PubMed Web of Science ®Google Scholar
• Stocker CF, Shekerdemian LS, Norgaard MA et al. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass. Crit. Care Med.35(1), 252–259 (2007).
   PubMed Web of Science ®Google Scholar
• Monrad ES, McKay RG, Baim DS et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation70(6), 1030–1037 (1984).
   PubMed Web of Science ®Google Scholar
• Albrecht CA, Giesler GM, Kar B, Hariharan R, Delgado RM 3rd. Intravenous milrinone infusion improves congestive heart failure caused by diastolic dysfunction: a brief case series. Tex. Heart Inst. J.32(2), 220–223 (2005).
   PubMed Web of Science ®Google Scholar
• Lakshminrusimha S, Porta N, Farrow K et al. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr. Crit. Care Med.10(1), 106–112 (2009).
   PubMed Web of Science ®Google Scholar
• Joynt C, Bigam D, Charrois G, Jewell L, Korbutt G, Cheung P. Dose–response effects of milrinone on hemodynamics of newborn pigs with hypoxia–reoxygenation. Intensive Care Med.34(7), 1321–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Cai J, Su Z, Shi Z, Zhou Y, Xu Z, Yang Y. Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan-type procedure: a prospective, randomized study. Ann. Thorac. Surg.86(3), 882–888 (2008).
   PubMed Web of Science ®Google Scholar
• Khazin V, Kaufman Y, Zabeeda D et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J. Cardiothorac. Vasc. Anesth.18(2), 156–159 (2004).
   PubMed Web of Science ®Google Scholar
• Chang A, Atz A, Wernovsky G, Burke R, Wessel D. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit. Care Med.23(11), 1907–1914 (1995).
   PubMed Web of Science ®Google Scholar
• McNamara P, Laique F, Muang-In S, Whyte H. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J. Crit. Care21(2), 217–222 (2006).
   PubMed Web of Science ®Google Scholar
• Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol. Neonate89(1), 1–5 (2006).
   PubMedGoogle Scholar
• Matot I, Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest125(2), 644–651 (2004).
   PubMed Web of Science ®Google Scholar
• Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit. Care Med.35(9), 2037–2050 (2007).
   PubMed Web of Science ®Google Scholar
• Paradisis M, Evans N, Kluckow M, Osborn D. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants. J. Pediatr.154(2), 189–195 (2009).
   PubMed Web of Science ®Google Scholar
• Lamarche Y, Malo O, Thorin E et al. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.130(1), 83–92 (2005).
   PubMed Web of Science ®Google Scholar
• Hentschel T, Yin N, Riad A et al. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology106(1), 124–131 (2007).
   PubMed Web of Science ®Google Scholar
• Haraldsson SA, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth. Analg.93(6), 1439–1445 (2001).
   PubMed Web of Science ®Google Scholar
• Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can. J. Anaesth.52(10), 1076–1082 (2005).
   PubMed Web of Science ®Google Scholar
• Denault AY, Lamarche Y, Couture P et al. Inhaled milrinone: a new alternative in cardiac surgery? Semin. Cardiothorac. Vasc. Anesth.10(4), 346–360 (2006).
   PubMedGoogle Scholar
• Lamarche Y, Perrault LP, Maltais S, Tetreault K, Lambert J, Denault AY. Preliminary experience with inhaled milrinone in cardiac surgery. Eur. J. Cardiothorac. Surg.31(6), 1081–1087 (2007).
   PubMed Web of Science ®Google Scholar
• Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir. Med.104(1), 9–21 (2009).
   PubMed Web of Science ®Google Scholar
• Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature263(5579), 663–665 (1976).
   PubMed Web of Science ®Google Scholar
• Grant S, Goa K. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs43(6), 889–924 (1992).
   PubMed Web of Science ®Google Scholar
• Herman A. Clinical use of prostaglandins in perspective. Acta Clin. Belg.38(2), 75–79 (1983).
   PubMed Web of Science ®Google Scholar
• Philips J 3rd, Lyrene R. Prostaglandins, related compounds, and the perinatal pulmonary circulation. Clin. Perinatol.11(3), 565–579 (1984).
   PubMed Web of Science ®Google Scholar
• Reyes J. Arachidonic acid metabolites and haemodynamics of the neonate. Pediatr. Nephrol.7(6), 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Shimokawa H, Flavahan NA, Lorenz RR, Vanhoutte PM. prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br. J. Pharmacol.95(4), 1197–1203 (1988).
   PubMed Web of Science ®Google Scholar
• Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am. J. Respir. Crit. Care Med.175(8), 846–850 (2007).
   PubMed Web of Science ®Google Scholar
• Obata H, Sakai Y, Ohnishi S et al. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med.177(2), 195–201 (2008).
   PubMed Web of Science ®Google Scholar
• Paramothayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst. Rev.2, CD002994 (2005).
   Google Scholar
• Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart93(6), 739–743 (2007).
   PubMed Web of Science ®Google Scholar
• Nakayama T, Shimada H, Takatsuki S et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. Circ. J.71(11), 1785–1790 (2007).
   PubMed Web of Science ®Google Scholar
• Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart94(Suppl. 1), i1–i41 (2008).
   PubMed Web of Science ®Google Scholar
• Lock J, Olley P, Coceani F, Swyer P, Rowe R. Use of prostacyclin in persistent fetal circulation. Lancet1(8130), 1343 (1979).
   PubMed Web of Science ®Google Scholar
• Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr. Cardiol.18(1), 3–7 (1997).
   PubMed Web of Science ®Google Scholar
• Golzand E, Bar-Oz B, Arad I. Intravenous prostacyclin in the treatment of persistent pulmonary hypertension of the newborn refractory to inhaled nitric oxide. Isr. Med. Assoc. J.7(6), 408–409 (2005).
   PubMed Web of Science ®Google Scholar
• Santak B, Schreiber M, Kuen P, Lang D, Radermacher P. Prostacyclin aerosol in an infant with pulmonary hypertension. Eur. J. Pediatr.154(3), 233–235 (1995).
   PubMed Web of Science ®Google Scholar
• Kaapa P, Koivisto M, Ylikorkala O, Kouvalainen K. Prostacyclin in the treatment of neonatal pulmonary hypertension. J. Pediatr.107(6), 951–953 (1985).
   PubMed Web of Science ®Google Scholar
• Drummond W, Williams B, Blanchard W. Myocardial infarction after prostacyclin (PGI2) treatment of neonatal pulmonary hypertension (PH). Pediatr. Res.16, 99A (1982).
   PubMed Web of Science ®Google Scholar
• Parker TA, Ivy DD, Kinsella JP et al. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Am. J. Respir. Crit. Care Med.155(2), 743–746 (1997).
   PubMed Web of Science ®Google Scholar
• Hougland KT, Null D, Ward RM. Epoprostenol use in PPHN. EPAS1239 (2005).
   Google Scholar
• Mangones T. Intravenous prostacyclin improves oxygenation in PPHN refractory to iNO. Abstract in: Pediatric Academic Societies’ Annual Meeting. E-PAS3360 (2005).
   Google Scholar
• Betremieux P, Rolland A, Prioul V, Beuchee A, Pladys P. Systemic hemodynamic effects of the association of inhaled nitric oxide and intravenous prostacyclin for persistent pulmonary hypertension of the newborn. Abstract in: Pediatric Academic Societies’ Annual Meeting. E-PAS2540 (2005).
   Google Scholar
• Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J. Pediatr.141(6), 830–832 (2002).
   PubMed Web of Science ®Google Scholar
• Max M, Rossaint R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur. J. Pediatr.158(Suppl. 1), S23–S26 (1999).
   PubMed Web of Science ®Google Scholar
• Rex S, Missant C, Claus P, Buhre W, Wouters PF. Effects of inhaled iloprost on right ventricular contractility, right ventriculo–vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension. Crit. Care12(5), R113 (2008).
   PubMedGoogle Scholar
• Noponen T, Nordh A, Berg A et al. Circulatory effects of inhaled iloprost in the newborn preterm lamb. Pediatr. Res.66(4), 416–422 (2009).
   PubMed Web of Science ®Google Scholar
• Welte M, Zwissler B, Habazettl H, Messmer K. PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur. Surg. Res.25(5), 329–340 (1993).
   PubMed Web of Science ®Google Scholar
• Ewert R, Schaper C, Halank M, Glaser S, Opitz CF. Inhalative iloprost – pharmacology and clinical application. Expert Opin. Pharmacother.10(13), 2195–2207 (2009).
   PubMed Web of Science ®Google Scholar
• Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc. Health Risk Manag.5(1), 325–331 (2009).
   PubMedGoogle Scholar
• Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin. Padiatr.220(2), 66–69 (2008).
   PubMed Web of Science ®Google Scholar
• Olmsted K, Oluola O, Parthiban A, Raghuveer T. Can inhaled prostacyclin stimulate surfactant in ELBW infants? J. Perinatol.27(11), 724–726 (2007).
   PubMed Web of Science ®Google Scholar
• De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as ‘rescue’ therapy for pulmonary hypertension of the neonate. Paediatr. Anaesth.17(4), 394–395 (2007).
   PubMed Web of Science ®Google Scholar
• Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiol. Young13(4), 361–363 (2003).
   PubMed Web of Science ®Google Scholar
• Bindl L, Fahnenstich H, Peukert U. Aerosolised prostacyclin for pulmonary hypertension in neonates. Arch. Dis. Child Fetal Neonatal Ed.71(3), F214–F216 (1994).
   PubMed Web of Science ®Google Scholar
• De Jaegere A, van den Anker J. Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. Eur. Respir. J.12(4), 932–934 (1998).
   PubMed Web of Science ®Google Scholar
• Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med.23(12), 1275–1278 (1997).
   PubMed Web of Science ®Google Scholar
• Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J. Med. Assoc. Thai.90(1), 167–170 (2007).
   PubMedGoogle Scholar
• Hsiao R OS. Inhaled aerosolized prostacyclin (IAP) for premature infants with PPHN. Abstract in Pediatric Academic Societies’ annual meeting. E-PAS3085 (2004).
   Google Scholar
• Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. Can. J. Physiol. Pharmacol.51(3), 220–225 (1973).
   PubMed Web of Science ®Google Scholar
• Smith GC. The pharmacology of the ductus arteriosus. Pharmacol. Rev.50(1), 35–58 (1998).
   PubMed Web of Science ®Google Scholar
• Naka Y, Roy D, Liao H et al. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ. Res.79(4), 773–783 (1996).
   PubMed Web of Science ®Google Scholar
• Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006. Heart95(4), 312–317 (2009).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation119(16), 2250–2294 (2009).
   PubMed Web of Science ®Google Scholar
• Hammerman C, Aramburo M, Choi J. Prostaglandin E1 selectively reduces group B β-hemolytic streptococci-induced pulmonary hypertension in newborn piglets. Am. J. Dis. Child.143(3), 343–347 (1989).
   PubMedGoogle Scholar
• Filan P, McDougall P, Shekerdemian L. Combination pharmacotherapy for severe neonatal pulmonary hypertension. J. Paediatr. Child Health42(4), 219–220 (2006).
   PubMed Web of Science ®Google Scholar
• Inamura N, Kubota A, Nakajima T et al. A proposal of new therapeutic strategy for antenatally diagnosed congenital diaphragmatic hernia. J. Pediatr. Surg.40(8), 1315–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Shiyanagi S, Okazaki T, Shoji H et al. Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone. Pediatr. Surg. Int.24(10), 1101–1104 (2008).
   PubMed Web of Science ®Google Scholar
• Iseri L, French J. Magnesium: nature’s physiologic calcium blocker. Am. Heart J.108(1), 188–193 (1984).
   PubMed Web of Science ®Google Scholar
• Doyle LW, Crowther CA, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet. Gynecol.113(6), 1327–1333 (2009).
   PubMed Web of Science ®Google Scholar
• Bhat MA, Charoo BA, Bhat JI, Ahmad SM, Ali SW, Mufti MU. Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial. Pediatrics123(5), e764–e769 (2009).
   PubMed Web of Science ®Google Scholar
• Ali A, Goldberg RN, Suguihara C et al. Effects of ATP-magnesium chloride on the cardiopulmonary manifestations of group B streptococcal sepsis in the piglet. Pediatr. Res.39(4 Pt 1), 609–615 (1996).
   PubMedGoogle Scholar
• Anderson ME, Burnette TM, Geiser DR, Janjindamai W. Magnesium attenuates pulmonary hypertension due to hypoxia and group B streptococci. J. Appl. Physiol.77(2), 751–756 (1994).
   PubMed Web of Science ®Google Scholar
• Barrington KJ, Ryan CA, Finer NN. Effects of magnesium sulfate in a newborn piglet meconium aspiration model. J. Perinatol.20(6), 373–378 (2000).
   PubMedGoogle Scholar
• Beghetti M, Spahr-Schopfer I, Mensi N, Morel D, Rimensberger P. Effects of inhaled nitric oxide and intravenous magnesium sulphate, alone and in combination, in a porcine model of hypoxic pulmonary hypertension. Med. Sci. Monit.9(6), BR193–BR198 (2003).
   PubMedGoogle Scholar
• Ryan C, Finer N, Barrington K. Effects of magnesium sulphate and nitric oxide in pulmonary hypertension induced by hypoxia in newborn piglets. Arch. Dis. Child Fetal Neonatal Ed.71(3), F151–F155 (1994).
   PubMed Web of Science ®Google Scholar
• Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. Arch. Dis. Child. Fetal Neonatal Ed.72(3), F184–F187 (1995).
   PubMed Web of Science ®Google Scholar
• Wu TJ, Teng RJ, Tsou KI. Persistent pulmonary hypertension of the newborn treated with magnesium sulfate in premature neonates. Pediatrics96(3 Pt 1), 472–474 (1995).
   PubMed Web of Science ®Google Scholar
• Daffa SH, Milaat WA. Role of magnesium sulphate in treatment of severe persistent pulmonary hypertension of the neoborn. Saudi Med. J.23(10), 1266–1269 (2002).
   PubMed Web of Science ®Google Scholar
• Chandran S, Haqueb ME, Wickramasinghe HT, Wint Z. Use of magnesium sulphate in severe persistent pulmonary hypertension of the newborn. J. Trop. Pediatr.50(4), 219–223 (2004).
   PubMed Web of Science ®Google Scholar
• Raimondi F, Migliaro F, Capasso L et al. Intravenous magnesium sulphate vs. inhaled nitric oxide for moderate, persistent pulmonary hypertension of the newborn. A multicentre, retrospective study. J. Trop. Pediatr.54(3), 196–199 (2008).
   PubMed Web of Science ®Google Scholar
• Ho J, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst. Rev.3, CD005588 (2007).
   Google Scholar
• Abu-Osba Y, Galal O, Manasra K, Rejjal A. Treatment of severe persistent pulmonary hypertension of the newborn with magnesium sulphate. Arch. Dis. Child.67(1 Spec. No.), 31–35 (1992).
   PubMed Web of Science ®Google Scholar
• Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr. Pulmonol.39(6), 492–503 (2005).
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature332(6163), 411–415 (1988).
   PubMed Web of Science ®Google Scholar
• Abman SH. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu. Rev. Med.60, 13–23 (2009).
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl J. Med.328(24), 1732–1739 (1993).
   PubMed Web of Science ®Google Scholar
• Davenport A, Maguire J. Endothelin. Handb. Exp. Pharmacol. (176 Pt 1), 295–329 (2006).
   PubMedGoogle Scholar
• Galie N, Rubin L, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet371(9630), 2093–2100 (2008).
   PubMed Web of Science ®Google Scholar
• Rubin L, Badesch D, Barst R et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.346(12), 896–903 (2002).
   PubMed Web of Science ®Google Scholar
• Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst. Rev.3, CD004434 (2009).
   Google Scholar
• Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr. Vasc. Pharmacol.7(2), 225–233 (2009).
   PubMed Web of Science ®Google Scholar
• Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J.29(16), 1936–1948 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenberg A, Kennaugh J, Koppenhafer S, Loomis M, Chatfield B, Abman S. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J. Pediatr.123(1), 109–114 (1993).
   PubMed Web of Science ®Google Scholar
• Peng J, Ladino J, Hehre D, Bancalari E, Suguihara E. Effects of a selective endothelin A (ETA) receptor antagonist on GBS-induced pulmonary hypertension in newborn piglets. Abstract in Pediatric Academic Societies’ annual meeting. E-PAS2443 (2003).
   Google Scholar
• Kuo C. Endothelin-A receptor antagonist prevents neonatal pulmonary hypertension in meconium aspiration in piglets. J. Formos. Med. Assoc.100(6), 420–423 (2001).
   PubMed Web of Science ®Google Scholar
• Nakwan N, Choksuchat D, Saksawad R, Thammachote P. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr.98(10), 1683–1685 (2009).
   PubMed Web of Science ®Google Scholar
• Goissen C, Ghyselen L, Tourneux P et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur. J. Pediatr.167(4), 437–440 (2008).
   PubMed Web of Science ®Google Scholar
• Konduri G, Theodorou A. Nitro-l-arginine attenuates pulmonary vasodilation caused by adenosine in fetal lambs. Pediatr. Res.31, 62 (1992).
   Google Scholar
• Cooper D, Lewis G, Lieberman G, Webb H, Westwick J. ADP metabolism in vascular tissue, a possible thrombo-regulatory mechanism. Thromb. Res.14(6), 901–914 (1979).
   PubMed Web of Science ®Google Scholar
• Konduri G, Woodard L, Mukhopadhyay A, Deshmukh D. Adenosine is a pulmonary vasodilator in newborn lambs. Am. Rev. Respir. Dis.146(3), 670–676 (1992).
   PubMedGoogle Scholar
• Konduri G, Garcia D, Kazzi N, Shankaran S. Adenosine infusion improves oxygenation in term infants with respiratory failure. Pediatrics97(3), 295–300 (1996).
   PubMed Web of Science ®Google Scholar
• Konduri G, Gervasio C, Theodorou A. Role of adenosine triphosphate and adenosine in oxygen-induced pulmonary vasodilation in fetal lambs. Pediatr. Res.33(5), 533–539 (1993).
   PubMed Web of Science ®Google Scholar
• Patole S, Lee J, Whitehall J. Adenosine infusion in the management of a micropremi neonate with pulmonary hypertension. Indian Pediatr.36(3), 307–310 (1999).
   PubMedGoogle Scholar
• Patole S, Lee J, Buettner P, Whitehall J. Improved oxygenation following adenosine infusion in persistent pulmonary hypertension of the newborn. Biol. Neonate74(5), 345–350 (1998).
   PubMedGoogle Scholar
• Ng C, Franklin O, Vaidya M, Pierce C, Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr. Crit. Care Med.5(1), 10–13 (2004).
   PubMedGoogle Scholar
• Mark AE. Hypoxic pulmonary vasoconstriction. Essays Biochem.43, 61–76 (2007).
   PubMed Web of Science ®Google Scholar
• Shimoda LA, Sham JS, Sylvester JT. Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol. Res.49(5), 549–560 (2000).
   PubMed Web of Science ®Google Scholar
• Lakshminrusimha S, Russell JA, Steinhorn RH et al. Pulmonary hemodynamics in neonatal lambs resuscitated with 21%, 50%, and 100% oxygen. Pediatr. Res.62(3), 313–318 (2007).
   PubMed Web of Science ®Google Scholar
• Maltepe E, Saugstad OD. Oxygen in health and disease: regulation of oxygen homeostasis – clinical implications. Pediatr. Res.65(3), 261–268 (2009).
   PubMed Web of Science ®Google Scholar
• Sanderud J, Bjoro K, Saugstad OD. Oxygen radicals stimulate thromboxane and prostacyclin synthesis and induce vasoconstriction in pig lungs. Scand. J. Clin. Lab Invest.53(5), 447–455 (1993).
   PubMed Web of Science ®Google Scholar
• Lakshminrusimha S, Russell JA, Wedgwood S et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am. J. Respir. Crit. Care Med.174(12), 1370–1377 (2006).
   PubMed Web of Science ®Google Scholar
• Farrow KN, Lakshminrusimha S, Reda WJ et al. Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol.295(6), L979–L987 (2008).
   PubMed Web of Science ®Google Scholar
• Farrow KN, Groh BS, Schumacker PT et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ. Res.102(2), 226–233 (2008).
   PubMed Web of Science ®Google Scholar
• Lakshminrusimha S, Swartz DD, Gugino SF et al. Oxygen concentration and pulmonary hemodynamics in newborn lambs with pulmonary hypertension. Pediatr. Res.66(5), 539–544 (2009).
   PubMed Web of Science ®Google Scholar
• Brennan LA, Steinhorn RH, Wedgwood S et al. Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase. Circ. Res.92(6), 683–691 (2003).
   PubMed Web of Science ®Google Scholar
• Teng RJ, Eis A, Bakhutashvili I, Arul N, Konduri GG. Increased superoxide production contributes to the impaired angiogenesis of fetal pulmonary arteries with in utero pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol.297(1), L184–L195 (2009).
   PubMed Web of Science ®Google Scholar
• Firth AL, Yuan JX. Bringing down the ROS: a new therapeutic approach for PPHN. Am. J. Physiol. Lung Cell Mol. Physiol.295(6), L976–L978 (2008).
   PubMed Web of Science ®Google Scholar
• Gong MC, Fujihara H, Walker LA, Somlyo AV, Somlyo AP. Down-regulation of G-protein-mediated Ca2+ sensitization in smooth muscle. Mol. Biol. Cell8(2), 279–286 (1997).
   PubMedGoogle Scholar
• Gong MC, Fujihara H, Somlyo AV, Somlyo AP. Translocation of rhoA associated with Ca2+ sensitization of smooth muscle. J. Biol. Chem.272(16), 10704–10709 (1997).
   PubMed Web of Science ®Google Scholar
• Kimura K, Ito M, Amano M et al. Regulation of myosin phosphatase by rho and rho-associated kinase (rho-kinase). Science273(5272), 245–248 (1996).
   PubMed Web of Science ®Google Scholar
• Nossaman BD, Kadowitz PJ. The role of the RhoA/rho-kinase pathway in pulmonary hypertension. Curr. Drug Discov. Technol.6(1), 59–71 (2009).
   PubMedGoogle Scholar
• Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol.25(9), 1767–1775 (2005).
   PubMed Web of Science ®Google Scholar
• Barman SA, Zhu S, White RE. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc. Health Risk Manag.5, 663–671 (2009).
   PubMedGoogle Scholar
• Parker TA, Roe G, Grover TR, Abman SH. Rho kinase activation maintains high pulmonary vascular resistance in the ovine fetal lung. Am. J. Physiol. Lung Cell Mol. Physiol.291(5), L976–L982 (2006).
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Fagan KA, Gebb SA et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med.171(5), 494–499 (2005).
   PubMed Web of Science ®Google Scholar
• Katz SL, Adatia I, Louca E et al. Nebulized therapies for childhood pulmonary hypertension: an in vitro model. Pediatr. Pulmonol.41(7), 666–673 (2006).
   PubMed Web of Science ®Google Scholar
• Chen YF, Jowett S, Barton P et al. Clinical and cost–effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol. Assess.13(49), 1–320 (2009).
   PubMed Web of Science ®Google Scholar
• Nadeau S, Baribeau J, Janvier A, Perreault T. Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr. Res.58(2), 199–205 (2005).
   PubMed Web of Science ®Google Scholar